Concurrent chemotherapy for T4 classification nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy.
Concurrent chemotherapy for T4 classification nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy.
复制标题
DOI：
10.1371/journal.pone.0119101
复制
发表时间：
2015
期刊：
影响因子：
3.7
通讯作者：
Xu GZ
中科院分区：
文献类型：
--
作者：
Cao CN;Luo JW;Gao L;Yi JL;Huang XD;Wang K;Zhang SP;Qu Y;Li SY;Xiao JP;Zhang Z;Xu GZ
目的探讨调强放疗（IMRT）治疗T4分型鼻咽癌的同期化疗效果。回顾性分析2004年7月至2011年6月180例非转移性T4型鼻咽癌患者。其中，117例患者接受同步放化疗（CCRT）联合IMRT治疗，63例患者单独接受IMRT治疗。中位随访时间58.97个月（范围2.79 ~ 114.92）个月。所有患者1、3、5年局部无故障生存率（LFFS）分别为97.7%、89.2%和85.9%，局部无故障生存率（RFFS）分别为98.9%、94.4%和94.4%，远端无故障生存率（DFFS）分别为89.7%、79.9%和76.2%，总生存率（OS）分别为92.7%、78.9%和65.3%。CCRT组与单独IMRT组的LFFS、RFFS、DFFS、OS差异均无统计学意义。除白细胞减少外，CCRT组与单独IMRT组在IMRT期间的急性毒性差异无统计学意义（p = 0.000）。与同期化疗加IMRT相比，单独IMRT治疗T4分类鼻咽癌在疾病局部控制和总生存方面取得了相似的治疗结果。然而，这是一项回顾性研究，患者数量有限，这些结果需要在前瞻性随机临床试验中进一步研究。
To evaluate concurrent chemotherapy for T4 classification nasopharyngeal carcinoma (NPC) treated by intensity-modulated radiotherapy (IMRT). From July 2004 to June 2011, 180 non-metastatic T4 classification NPC patients were retrospectively analyzed. Of these patients, 117 patients were treated by concurrent chemoradiotherapy (CCRT) using IMRT and 63 cases were treated by IMRT alone. The median follow-up time was 58.97 months (range, 2.79–114.92) months. For all the patients, the 1, 3 and 5-year local failure-free survival (LFFS) rates were 97.7%, 89.2% and 85.9%, regional failure free survival (RFFS) rates were 98.9%, 94.4% and 94.4%, distant failure-free survival (DFFS) rates were 89.7%, 79.9% and 76.2%, and overall survival (OS) rates were 92.7%, 78.9% and 65.3%, respectively. No statistically significant difference was observed in LFFS, RFFS, DFFS and OS between the CCRT group and the IMRT alone group. No statistically significant difference was observed in acute toxicity except leukopenia (p = 0.000) during IMRT between the CCRT group and the IMRT alone group. IMRT alone for T4 classification NPC achieved similar treatment outcomes in terms of disease local control and overall survival as compared to concurrent chemotherapy plus IMRT. However, this is a retrospective study with a limited number of patients, such results need further investigation in a prospective randomized clinical trial.
登录
查看更多内容
影响因子：
4.6
作者：
Kim, Tae Hee;Ko, Yoon Ho;Kang, Jin-Hyoung
通讯作者：
Kang, Jin-Hyoung
DOI：
10.1016/s0360-3016(00)00702-1
发表时间：
2000-10-01
影响因子：
7
作者：
Sultanem, K;Shu, HK;Fu, KK
通讯作者：
Fu, KK
影响因子：
45.3
作者：
Langendijk, JA;Leemans, CR;Slotman, BJ
通讯作者：
Slotman, BJ
影响因子：
3.1
作者：
DAHL, O;HORN, A;MELLA, O
通讯作者：
MELLA, O
影响因子：
5.7
作者：
Sun, Xueming;Su, Shengfa;Lu, Taixiang
通讯作者：
Lu, Taixiang